Analysis and treatment options for small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on small cell lung cancer (SCLC), an aggressive form of lung cancer known for rapid growth and early metastasis. It aims to explore the molecular characteristics and immunologic microenvironment of SCLC to improve disease classification and treatment strategies. By identifying molecular alterations, the study seeks to enhance predictions of patient response to novel therapies and ongoing clinical trials. The research highlights the need for reliable biomarkers to improve long-term outcomes for patients with SCLC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven diagnosis of SCLC
* 18 years of age or older
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Histologically proven diagnosis of non-SCLC

Where it's running

• Shanghai Chest Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Xiaomin Niu
• Email: ar_tey@hotmail.com, artey@sjtu.edu.cn
• Phone: 021-22200000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• DSP-0390 with Atezolizumab in extensive-stage small cell lung cancer

  This pilot phase Ib study tests whether adding DSP-0390 to maintenance atezolizumab after initial chemo-immunotherapy is safe and shows early signs of activity in people with extensive-stage small cell lung cancer who have not progressed.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07545954

• Autologous B7-H3 CAR T Cells in Advanced Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

  This study tests a patient’s own B7-H3 CAR T cells to see if they can help people 18 and older whose small cell lung cancer or EPNEC has come back or hasn’t responded to prior treatment.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07509034

• Hospital-at-Home program for patients receiving Tarlatamab

  This study is testing if a Hospital-at-Home program can help adults with advanced small cell lung cancer who are getting tarlatamab feel better while being monitored from home instead of staying in the hospital.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06957314

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.